13F HOLDINGS REPORT
Aisling Capital Management LP
Quarter ended Q4 2024 · Filed February 12, 2025 · Accession 0001766721-25-000001
Total Value
$281.8M
Positions
15
Other Managers
0
Confidential Omitted
No
Holdings (15)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 6,068,125 | $166.5M | 59.08% |
| 2 | Verona Pharma plc (VRNA) | 925050106 | 1,115,352 | $51.8M | 18.38% |
| 3 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 1,025,000 | $13.6M | 4.81% |
| 4 | Monte Rosa Therapeutics Inc (GLUE) | GLUE | 1,472,331 | $10.2M | 3.63% |
| 5 | Poseida Therapeutics Inc. (PSTX) | 73730P108 | 1,043,267 | $10.0M | 3.55% |
| 6 | Bicara Therapeutics Inc. (BCAX) | BCAX | 568,919 | $9.9M | 3.52% |
| 7 | Nuvation Bio Inc. (NUVB) | NUVB | 2,541,009 | $6.8M | 2.40% |
| 8 | Compass Pathways Plc (CMPS) | CMPS | 964,500 | $3.6M | 1.29% |
| 9 | Biomea Fusion Inc (BMEA) | BMEA | 798,757 | $3.1M | 1.10% |
| 10 | CalciMedica, Inc. (CALC) | CALC | 521,114 | $1.8M | 0.65% |
| 11 | Elevation Oncology Inc (ELEV) | 28623U101 | 2,834,910 | $1.6M | 0.56% |
| 12 | Aclaris Therapeutics Inc (ACRS) | ACRS | 434,455 | $1.1M | 0.38% |
| 13 | Marker Therapeutics, Inc. (MRKR) | MRKR | 325,370 | $1.0M | 0.36% |
| 14 | OnKure Therapeutics, Inc. (OKUR) | OKUR | 88,607 | $762,020 | 0.27% |
| 15 | Viracta Therapeutics Inc (VIRX) | 92765F108 | 288,571 | $46,171 | 0.02% |